The effects of HAPA theory-based case management in patients with metabolic dysfunction-associated steatotic liver disease

IF 4.4 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Annals of hepatology Pub Date : 2025-02-14 DOI:10.1016/j.aohep.2025.101790
Jia Mei, Yuncai Xie, Pingping Huang, Yudi Jin, Xia Wang, Ying Chen
{"title":"The effects of HAPA theory-based case management in patients with metabolic dysfunction-associated steatotic liver disease","authors":"Jia Mei,&nbsp;Yuncai Xie,&nbsp;Pingping Huang,&nbsp;Yudi Jin,&nbsp;Xia Wang,&nbsp;Ying Chen","doi":"10.1016/j.aohep.2025.101790","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting people's health, with its incidence increasing year by year. This study aims to determine the effects of Health Action Process Approach (HAPA)-based health management on patients diagnosed with MASLD.</div></div><div><h3>Patients and Methods</h3><div>204 MASLD patients were selected from the hospital's physical examination center from January 1, 2023, through April 1, 2023. Patients are randomly assigned to two groups (<em>n</em> = 102 each) using an envelope-based. Individuals in the experimental group received case management based on the HAPA theory, while standard health management was employed for control group patients. All subjects were monitored over a 6-month period, comparing body mass index (BMI), waist-to-hip ratio (WHR), levels of liver function (AST, ALT), blood lipid levels (total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and health behaviours (as assessed with the HPLP-II health promotion lifestyle scale) before and after the intervention.</div></div><div><h3>Results</h3><div>Post-intervention, the experimental group showed significant improvement in fatty liver (<em>P</em> &lt; 0.01) and reductions in biochemical indices, BMI, and WHR levels (<em>P</em> &lt; 0.05), and a corresponding improvement in HDL-C levels (<em>P</em> &lt; 0.001), compared to the control group. Additionally, patients in the experimental group exhibited significantly better health behaviour scores related to stress management, exercise, diet, and health responsibility compared to controls (<em>P</em> &lt; 0.01).</div></div><div><h3>Conclusions</h3><div>HAPA theory-based case management can improve blood lipid profiles, liver function, and health-related behaviours in MASLD patients, highlighting its potential as an effective management strategy for this condition.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101790"},"PeriodicalIF":4.4000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268125000146","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and Objectives

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting people's health, with its incidence increasing year by year. This study aims to determine the effects of Health Action Process Approach (HAPA)-based health management on patients diagnosed with MASLD.

Patients and Methods

204 MASLD patients were selected from the hospital's physical examination center from January 1, 2023, through April 1, 2023. Patients are randomly assigned to two groups (n = 102 each) using an envelope-based. Individuals in the experimental group received case management based on the HAPA theory, while standard health management was employed for control group patients. All subjects were monitored over a 6-month period, comparing body mass index (BMI), waist-to-hip ratio (WHR), levels of liver function (AST, ALT), blood lipid levels (total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and health behaviours (as assessed with the HPLP-II health promotion lifestyle scale) before and after the intervention.

Results

Post-intervention, the experimental group showed significant improvement in fatty liver (P < 0.01) and reductions in biochemical indices, BMI, and WHR levels (P < 0.05), and a corresponding improvement in HDL-C levels (P < 0.001), compared to the control group. Additionally, patients in the experimental group exhibited significantly better health behaviour scores related to stress management, exercise, diet, and health responsibility compared to controls (P < 0.01).

Conclusions

HAPA theory-based case management can improve blood lipid profiles, liver function, and health-related behaviours in MASLD patients, highlighting its potential as an effective management strategy for this condition.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于HAPA理论的病例管理在代谢功能障碍相关脂肪变性肝病患者中的作用
简介与目的:代谢功能障碍相关性脂肪变性肝病(MASLD)是影响人们健康的最常见的肝脏疾病,其发病率呈逐年上升趋势。本研究旨在探讨以健康行动过程方法(HAPA)为基础的健康管理对MASLD患者的影响。患者和方法:选取2023年1月1日至2023年4月1日在该院体检中心就诊的MASLD患者204例。采用包络法将患者随机分为两组(n = 102)。实验组采用HAPA理论的病例管理,对照组采用标准健康管理。对所有受试者进行为期6个月的监测,比较干预前后的体重指数(BMI)、腰臀比(WHR)、肝功能水平(AST、ALT)、血脂水平(总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和健康行为(用HPLP-II健康促进生活方式量表评估)。结论:基于HAPA理论的病例管理可以改善MASLD患者的血脂谱、肝功能和健康相关行为,突出了其作为一种有效管理策略的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of hepatology
Annals of hepatology 医学-胃肠肝病学
CiteScore
7.90
自引率
2.60%
发文量
183
审稿时长
4-8 weeks
期刊介绍: Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
期刊最新文献
Metabolic dysfunction-associated steatotic liver disease: No alcohol. Re-evaluating serum IL-6 as a prognostic biomarker in HCC immunotherapy with atezolizumab plus bevacizumab: the critical role of baseline liver function and disease etiology. Reply to: Comment on "pancreatic involvement and its prognostic impact in acute-on chronic liver failure". ALEH position statement on the management of hepatitis B virus infection 2025. Adult-to-adult living donor liver transplantation in a low-middle income country setting: eight-year experience from Colombia's first program.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1